

Food and Drug Administration
Department of Health and Human Services

Homeopathic Product Regulation: Evaluating the Food and Drug Administration's Regulatory Framework After a Quarter-Century
Part 15 Public Hearing

Presiding Officer

John J. Whyte, M.D., M.P.H.

Director, Professional Affairs and Stakeholder Engagement
Center for Drug Evaluation and Research

Panel Members

Kate Bent, R.N., Ph.D.

Assistant Commissioner for Compliance Policy
Director, Office of Policy and Risk Management, Office of Regulatory Affairs

Rima Izem, Ph.D.

Lead Mathematical Statistician, Division of Biometrics VII, Office of Biostatistics
Office of Translational Sciences, Center for Drug Evaluation and Research

Elaine Lippmann, J.D.

Regulatory Counsel
Office of Regulatory Policy, Center for Drug Evaluation and Research

Richard (Rik) Lostritto, Ph.D.

Director, Division of Internal Policies and Procedures, Office of Pharmaceutical Policy
Office of Pharmaceutical Quality, Center for Drug Evaluation and Research

Theresa Michele, M.D.

Director, Division of Nonprescription Drug Products
Office of New Drugs, Center for Drug Evaluation and Research

Judy McMeekin, Pharm.D.

Director, Medical Products and Tobacco Policy Staff
Office of Policy and Risk Management, Office of Regulatory Affairs

Robert 'Skip' Nelson, M.D., M.Div., Ph.D.

Deputy Director and Senior Pediatric Ethicist
Office of Pediatric Therapeutics, Office of the Commissioner

Brad Pace, J.D.

Supervisory Regulatory Counsel
Office of Compliance, Center for Drug Evaluation and Research

Charles G. Wu, Ph.D.

Pharmacognosy and Pharmacology Reviewer
Office of Pharmaceutical Quality, Center for Drug Evaluation and Research